SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
PZ Cussons has decided to leave Nigeria, citing naira's devaluation as the reason after GSK, Sanofi and other multinationals ...
Clayton Dubilier & Rice is discussing the possibility of using borrowed money to fund a part of the equity check in its bid ...
Panacea has agreed to forego its claim for damages & rendition of accounts in the proceedings against Sanofi as prayed in the ...
Panacea Biotec has reached a settlement with Sanofi Healthcare India concerning a patent infringement for its fully liquid ...
Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...
Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a ...
Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...
Advisors Capital Management partner and portfolio manager JoAnne Feeney joins Morning Brief to discuss the political outlook for small caps (^RUT) and some of her top tech plays as the market ...